Finally, to assess clinical significance of these proteins, we collected clinical data from 12 newly diagnosed AML patients and analyzed the correlation between plasma TNFAIP8, TCL1A, WFDC1, and TNFSF8 protein levels and patient clinical features. This evidence concerns the gene TCL1A and acute myeloid leukemia.